Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. Recherche
  • icone plus

  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte

  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités

2 results

  • Language : Français
  • Topics : Mental disorders and behavioural conditions
  • Active substance : venlafaxine
Filter
Topic
  • Diseases and conditions (2)
  • Plus ...
    • Mental disorders and behavioural conditions (2)
    • Plus ...
      • Anxiety and neurotic disorders (1)
      • Eating and sleep disorders (1)
      • Depression and mood disorders (1)
  • Diagnostic and therapeutic techniques (1)
  • Plus ...
    • Drug therapy (1)
  • Population groups (1)
  • Plus ...
    • Paediatrics (1)
Content type
  • Drugs, devices and medical acts (1)
  • Plus ...
    • Medicine (1)
  • Practice Guidelines and Other Guides (1)
  • Plus ...
    • Practice guidelines (1)
Langue
  • Français (2)
Substance active
  • alcool (1)
  • amitriptyline (1)
  • citalopram (1)
  • escitalopram (1)
  • lamotrigine (1)
  • lithium (1)
  • orlistat (1)
  • potassium (1)
  • sodium (1)
  • topiramate (1)
  • tryptophane (1)
  • venlafaxine (2)
  • zinc (1)
  • zonisamide (1)
More filter Other Filter Icon
Search Export

Practice guidelines and other guides - 1 result

  • Bulimia nervosa and binge eating disorder

    Practice guidelines - Posted on 12/9/2019
    Download abstract
    Add to my selection

Drugs, devices and medical acts - 1 result

  • EFFEXOR (venlafaxine (chlorhydrate de))

    Medicine - Posted on 5/7/2017 - Mis à jour le 12/6/2019
    Add to my selection

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
F16p0aFL3QwtjpqU